The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

Combination therapy strategies that induce immune responses may expand the utility of ICIs. Here, we investigated the safety and efficacy of PROSTVAC, a therapeutic cancer vaccine that targets ...

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight ...

Under the terms of the agreement, Immuno Cure will use PharmaJet’s Tropis ID system in a human clinical trial to deliver their novel HIV-1 therapeutic DNA Vaccine (ICVAX). The agreement was executed ...

Neoadjuvant therapy, treatment prior to surgical resection, is generally used to reduce tumor size in order to reduce the extent of surgery required, sparing healthy tissue and thereby decrease the ...

Elicio’s pipeline includes additional off-the-shelf therapeutic cancer vaccines candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively.

A brain cancer shot has delivered early clinical data, while a lung cancer immunotherapy was cleared in April for human testing. The deal should help CureVac because of “the early stage of the ...

We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to ...

The scientists have developed a therapeutic vaccine based on a recombinant protein called Terah-7, which is capable of stimulating the immune system to fight cancer caused by HPV. Imunotera was ...

A new breast cancer vaccine will be moving forward to the next stages of development and may soon be able to stop cancerous tumors from forming. Here’s what you need to know.

Now, researchers at Case Western Reserve University and Cleveland Clinic are developing vaccines targeting pancreatic cancer that could eliminate the disease, leaving a patient cancer-free.

The researchers received a $3.27 million, five-year grant from the National Cancer Institute to further explore the therapeutic use of vaccines in preclinical models of PDAC.